Jeffrey Wiezorek, SVP Clinical Development at Kite Pharma, Inc. (KITE), sold 1,500 shares at $50.68 ($76K) on 2016-12-01, disclosed to the SEC on 2016-12-05.
Open-market sale of $76k KITE by SVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.68 | 1,293 | $66K | 86.1% |
| 2 | $51.23 | 207 | $11K | 13.9% |
| Total | $50.76 avg | 1,500 | $76K | 100% |
| Filing → |
| KITE | SELL | 2017-03-02 | $1.4M | — | Filing → |
| KITE | SELL | 2017-02-06 | $77K | — | Filing → |
| KITE | SELL | 2017-01-10 | $75K | — | Filing → |